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Summary statement  
This paper provides a comprehensive characterisation of the short-term effects of 




Mice are a widely used pre-clinical model system in large part due to their potential for 
genetic manipulation. The ability to manipulate gene expression in specific cells under temporal 
control is a powerful experimental tool. The liver is central to metabolic homeostasis and a site of 
many diseases, making the targeting of hepatocytes attractive. Adeno-Associated Virus 8 (AAV8) 
vectors are valuable instruments for the manipulation of hepatocellular gene expression. However, 
their off-target effects in mice have not been thoroughly explored. Here, we sought to identify the 
short-term off-target effects of AAV8 administration in mice. To do this, we injected C57BL/6J Wild-
Type mice with either recombinant AAV8 vectors expressing Cre recombinase or control AAV8 
vectors and characterised the changes in general health and in liver physiology, histology and 
transcriptomics compared to uninjected controls. We observed an acute and transient trend for 




















γH2AX following AAV8 administration. The latter was enhanced upon Cre recombinase expression by 
the vector. Furthermore, we observed transcriptional changes in genes involved in circadian rhythm 
and response to infection. Notably, there were no additional transcriptomic changes upon 
expression of Cre recombinase by the AAV8 vector. Overall, there was no evidence of liver injury, 
and only mild T-cell infiltration was observed 28 days following AAV8 infection. These data advance 
the technique of hepatocellular genome editing through Cre-Lox recombination using Cre expressing 
AAV vectors, demonstrating their minimal effects on murine physiology and highlight the more 
subtle off target effects of these systems. 
 
Introduction 
Animal models have improved our understanding and therapies for human disease. The 
mouse is a prototypical model organism that is widely used for a number of reasons, including its 
similarities with human physiology, breeding efficiency and ease of handling, cost efficiency and the 
range of available genetic models. Due to the latter particularly, mice have become the most widely 
used in vivo pre-clinical model system (Rosenthal and Brown, 2007). Manipulation of gene 
expression in this model organism has come a long way from whole body knock-out (KO) to the 
current point that we are able to introduce point mutations in a tissue specific manner through 
CRISPR-Cas9 genomic editing (Sauer and Henderson, 1988; Wilson, 1996; Lee, Yoon and Kim, 2020; 
Lundin et al., 2020). The Cre-Lox system, although less flexible compared to CRISPR, remains widely 
used for the manipulation of gene expression in mice and is a readily applicable means of genomic 
editing with high reproducibility.  
Taking advantage of the Cre-Lox system, Adeno-Associated Viruses (AAVs) are an important 
vector system for gene expression manipulation and their use has risen dramatically in the last 20 
years. As AAVs are replication deficient, they are a relatively safe and efficient way to express the Cre 
recombinase, overexpress specific proteins or introduce shRNA into in vivo model systems. AAVs are 
small (20nm), single-stranded DNA viruses that belong to the family of Parvoviridae. They elicit a 
very mild immune response, especially the recombinant AAV vectors (rAAVs) which have undergone 
modifications to partly evade the immune system (Rogers et al., 2011; Rabinowitz, Chan and 
Samulski, 2019). There are different serotypes of AAV (AAV1, 2, 4, 5, 6, 7, 8, and 9), each of which 
exhibits a various transduction efficiencies in the different target tissues (Zincarelli et al., 2008). In 
mice, after  transfecting their target cells, AAVs enter the cell nucleus where they persist in an 






















The liver is the largest solid organ in the body and is a frequent site of organ-specific and 
systemic diseases and a frequent site of tumour metastasis. In liver biology, studying hepatocytes is 
particularly important as they constitute the majority of liver cells, comprising around 80% of total 
liver mass. Hepatocytes perform most of the synthetic and detoxification functions of the liver, are 
major contributors to liver regeneration and are the cell of origin for the majority of primary liver 
cancers (Müller, Bird and Nault, 2020). As a result, genetic manipulation of hepatocytes is a powerful 
tool in the study of liver disease. 
 
There are a number of ways to manipulate hepatocellular gene expression (Kellendonk et al., 
2000). Currently, a widely used approach is to target hepatocytes with an AAV-based vector. rAAV8 
is a commonly used AAV serotype due to its strong propensity to transduce hepatocytes (Nakai et al., 
2005). rAAV8-mediated hepatocellular gene editing has multiple applications including gene therapy 
(Smith et al., 2011), lineage tracing experiments, gene deletion or gene overexpression in all or 
specific populations of the hepatocytes. Through the insertion of tissue specific promoters 
expression of the vector’s “cargo” can be further cell type-restricted. In particular, the Cre 
recombinase together with a hepatocyte-specific promoter like the Thyroxin Binding Globulin (TBG) 
promoter can be incorporated into the AAV8 genome and this is reported to be a specific means of 
Cre recombinase expression in hepatocytes, while avoiding undesired expression in extrahepatic 
cells (Nakai et al., 2005; Malato et al., 2011; Lee et al., 2020). The number of transduced hepatocytes 
is proportional to the dose (i.e. genetic copies) of AAV8-TBG vector that are administered; the higher 
the dose of the vector, the more hepatocytes will be transduced. This allows the study of 
deleting/overexpressing a gene in the whole liver parenchyma (Bird et al., 2018) or in a small 
number of hepatocytes using comparatively fewer genetic copies of vector. Alternatively, instead of 
the Cre recombinase, it is possible to deliver other constructs as cargo (e.g. expression of shRNAs or 
ectopic proteins) to hepatocytes using this approach; for example, administration of the AAV8-TBG-
P21 vector results in P21 overexpression in hepatocytes, inhibiting their ability to proliferate (Raven 
et al., 2017). Expression of ectopic proteins with AAV vectors has been reported to last for several 
months, at least in post-mitotic cells (Duan et al., 1999).  
 
The AAV8 system theoretically allows for manipulation of gene expression at a desired time 
point and without inducing toxicity or the risk of genetic “leakiness” through an endogenous Cre 
allele. This is in comparison to other models like the Albumin-Cre mice, where the Cre recombinase 
is constitutively expressed from embryonic life and is therefore not temporally controlled, or 




















toxicity (Gao et al., 2016; Keeley, Horita and Samuelson, 2019). As such, AAV8-TBG is widely used in 
order to recombine the majority of the hepatocytes and study the effects of gene expression 
changes in the whole liver serving as a single hit, hepatocyte-specific gene knock-
out/overexpression.  
 
With the report that AAVs may have long lasting effects upon the liver epithelium, including 
rare cancers, it is clear that transduction with AAV is not entirely benign (Nault et al., 2015). Even 
though in humans evidence suggests that the immune system might compromise AAV8 efficiency 
(partly due to cross-immunity with Adenoviruses) there haven’t been detailed studies on the murine 
immune response against AAV8 (Boutin et al., 2010; Mendell et al., 2010; Calcedo et al., 2011). 
Furthermore, as rAAV8 rarely integrates into the murine host genome, it seems unlikely that it would 
cause significant genotoxicity. In one study investigating the long term effects of AAV2-hFIX16 (which 
results in liver-specific expression of clotting factor IX) in liver tumourigenesis in mice, it was found 
that there was no association between tissue from hepatocellular carcinomas (HCCs) and AAV copy 
numbers (Li, Malani and Hamilton, 2011).  
 
Transcriptome-wide studies are commonly performed on whole liver lysates or isolated liver 
cell fractions of mice treated with AAV8-TBG-Cre. These transcriptomics analyses can give valuable 
information on the effects following manipulation of hepatocellular gene expression via AAV8-TBG-
Cre. However, a potential effect on the transcriptome by the AAV8 vector or by its cargo (i.e. the Cre 
recombinase or other protein expressed by the vector) should be taken into consideration when 
performing and interpreting such studies. To our knowledge there are currently no studies 
addressing whether AAV vectors (and in particular AAV8-TBG) alone have an effect on the liver 
transcriptome.  
 
Overall, there is a lack of descriptive studies on the effects of systemic AAV8 administration in 
mice. Therefore, to address this shortfall we investigated the short-term off-target effects of 
systemic AAV8-TBG administration in Wild-Type (WT) mice. After intravenous (i.v.) injection of AAV8-
TBG-Cre (expressing Cre recombinase) or AAV8-TBG-Null (expressing a scrambled sequence) at 
dosing resulting in transduction across the majority of the hepatocellular compartment we examined 
both liver specific and systemic alterations in WT mice. Using blood analysis combined with 
immunohistochemistry and transcriptomics analysis we describe the effects occurring over  2 weeks 
post transduction. These data confirm minor off target effects following transduction using this 





















AAV8-TBG is hepatocyte-specific. 
We first examined the tissue and cell specificity of AAV8-TBG using mice homozygous for the 
R26-LSL-tdTomato allele on a C57BL/6 background by simultaneous injection with AAV8-TBG-Cre and 
AAV8-TBG-GFP (herein referred to as AAV-Cre and AAV-GFP respectively) (Fig. 1A). The cells 
expressing the Green Fluorescent Protein (GFP) and Red Fluorescent Protein (RFP) reporters 7 days 
after AAV8 injection were assessed histologically first in the liver, demonstrating that the majority of 
the hepatocytes expressed the reporters (80-96% for RFP and 64-97% for GFP) (Fig. 1B, 1C, S1A, 
S1B), consistent with previous reports using this (Bird et al., 2018; Gay et al., 2019) and other AAV8-
Cre constructs (Malato et al., 2011). There was no evidence of recombination of biliary epithelium 
(Fig. 1D). Interestingly, while RFP staining was distributed evenly across the hepatocytes, the GFP 
distribution was more irregular and its intensity varied among hepatocytes, with a tendency for more 
intense staining in the hepatocytes surrounding the central vein (pericentral hepatocytes of Zone 3) 
(Fig. 1B). Notably, when we checked for reporter expression in other organs, we observed labelling 
of very few cells in the duodenum, kidney, pancreas, lung and the spleen (Fig. 1E, 1F). The apparent 
GFP positivity observed in the duodenum and the spleen of uninjected mice (Fig. 1E, inset images) 
appears as non-specific background staining. These data show, in agreement with other studies 
(Wang et al., 2010; Bell, Wang, et al., 2011), that AAV8-TBG-mediated gene targeting is highly 
specific for hepatocytes with negligible targeting of extra-hepatic tissues. 
 
Systemic administration of AAV8-TBG does not affect the general health of mice. 
To investigate the off-target effects of systemic AAV8-TBG administration, WT mice were i.v. 
injected with AAV8-TBG-Null (herein referred to as AAV-Null) or AAV-Cre. Mice were then culled 2, 4, 
7 or 14 days post AAV8-TBG injection and compared to uninjected controls using a number of clinical 
parameters (Fig. 2A). Starting at a similar body weight at day 0 (Fig. S1C), the mice showed no 
significant changes in body weight and gradually gained weight at a normal rate for their age during 
the 2 weeks following AAV-Null or AAV-Cre, regardless of the group (Fig. 2B). Haematology analysis 
showed no changes in haematocrit or platelets (Fig. 2C). Reflecting the reported mild inflammatory 
response elicited by AAVs, we did not observe significant changes in circulating total white blood 
cells, monocytes, neutrophils or lymphocytes (Fig. 2D, 2E, Fig. S1D). Overall, we did not observe any 





















AAV8-TBG vectors do not cause liver damage. 
Next, having demonstrated hepatocyte-specific targeting, we proceeded to assess the effects 
of AAV8-TBG on the liver specifically. Livers were normal macroscopically and we did not observe 
any changes in liver size or liver histology microscopically (as assessed by H&E staining) in response 
to AAV8-TBG (Fig. 2F, S1E, S2). Similarly, serum levels of Alanine aminotransferase (ALT) and Alkaline 
phosphatase (ALP) (markers of liver necrosis and bile duct damage respectively) remained at 
baseline levels at every time point (Fig. 2G). Assessing liver function, serum bilirubin levels also 
remained unaffected as did serum levels of total protein and globulins (Fig 2G, S1F). We noticed a 
significant increase in albumin:globulins ratio in the blood, which was driven in part by a significant 
increase in serum albumin but also by a trend for reduction of serum globulins (Fig. S1F). Examining 
hepatic cell death in more detail, we performed immunohistochemistry for the apoptosis-specific 
marker Cleaved Caspase 3 (CC3). No changes in apoptotic cell death were observed at any time point 
(Fig. S1G, S2). There was no change in serum urea levels, however creatinine was significantly 
increased at day 4 and 14 in AAV-Null mice (Fig. S1H). Therefore, we found no evidence of liver 
damage and only observed mild dysfunction, as evidenced by the increase in serum albumin, after 
AAV8-TBG administration during the times when transduction and generic recombination occur. 
 
We next examined intrahepatic leukocyte populations to see whether a demonstrable local 
immune response occurred in the liver. Using the pan-leukocyte marker CD45, we didn’t observe any 
change in overall hepatic leukocyte numbers or distribution (Fig. 3A, S2). The use of more specific 
leukocyte markers for neutrophils (Ly6G), macrophages (F4/80) and T-cells (CD3) also demonstrated 
no significant differences in these populations either in number or distribution at any timepoint (Fig. 
3A, S2, S3). Therefore we find no evidence of histological inflammation or inflammatory response to 
biologically relevant AAV8 dosing. 
 
AAV8-TBG vectors affect the cell cycle of liver cells and induce expression of the DNA 
damage marker γH2AX in the liver. 
Viral infection of mammalian cells is, through a variety of well characterised mechanisms, 
known to affect several cellular processes including cell cycle, DNA damage response (DDR) and the 
release of Damage-Associated Molecular Patterns (DAMPs) (Loo and Gale, 2011; Dou et al., 2017; 
Motwani, Pesiridis and Fitzgerald, 2019). To address whether AAV8-TBG vectors can induce such 
changes, we first stained liver sections for the cell cycle inhibitor Cdkn1a (P21) or for BrdU to 
determine changes in the cell cycle status of liver cells. Whilst there was no significant change in 




















at day 2 post AAV8-TBG administration with a rebound at the 2 week time point (Fig. 3B, 3C, S3). 
Next, we assessed the presence and extent of hepatic DNA damage by staining liver sections for the 
DNA damage marker γH2AX. We observed a marked increase in γH2AX at day 2, persisting until day 7 
and falling at day 14 more prominently in the AAV-Null compared to AAV-Cre (Fig. 3D, S4). 
Moreover, treatment with AAV-Cre resulted in a stronger γH2AX response in the liver (Fig. 3D, S1I). 
Notably, γH2AX staining was stronger in the pericentral hepatocytes (Fig. 3E). While gene expression 
through AAV8-TBG is highly liver specific, AAV8 transduction is less well restricted. Therefore, we 
investigated whether there was induction of γH2AX in other organs prone to AAV8 transduction. To 
do this we stained spleen and kidney sections for γH2AX. We observed no γH2AX induction in the 
kidney and a trend for induction in the spleen, particularly localised within the red pulp (Fig. 3H, 3I, 
S4) Overall, our data reveal an acute and transient reduction in hepatic proliferation alongside a 
temporally-associated increased hepatocellular γH2AX expression following systemic AAV8 
administration. 
 
AAV8-TBG vectors induce circadian rhythm- and infection-related transcriptional 
changes.  
As a broader and unbiased assessment of the effects of AAV8-TBG vectors we next explored 
their effect on the liver transcriptome by performing RNA-seq on whole liver lysates from the AAV8-
TBG-treated and uninjected control mice (Fig. 4A). In general, there was a strong degree of similarity 
among all samples by Principal Component Analysis (PCA) (Fig. 4B). We interrogated this 
transcriptomics data in more detail, starting with the AAV8-TBG cargo in each group. Here we 
observed that there was a gradual increase in the number of the respective AAV8-TBG transcripts 
detected from day 2 to day 7 (Fig. 4C). Transcript number was also influenced by the specific cargo; 
expression of Cre transcript was lower than that of the transcript expressed by AAV-Null. Our 
analysis identified 235, 72, 860, 391, 265 and 184 genes that were differentially expressed between 
uninjected and AAV-Null day 2, AAV-Null day 4, AAV-Null day 7, AAV-Cre day 2, AAV-Cre day 4 and 
AAV-Cre day 7 groups respectively (Fig. 4D). Next, we performed pathway analysis in order to 
identify global transcriptional changes. This revealed two broad transcriptional programmes that 
were altered among the different timepoints; immune response-related changes and circadian 
rhythm changes (Fig. 4E). This is further supported by the observation that several immune-related, 
genes including the principally monocyte chemoattractants Ccl2 and Cxcl9/10, are consistently 
differentially expressed in all groups compared to the uninjected group (Fig. S5). Notably, using this 





















Having observed prominent effects on cellular proliferation at day 2, we focused on the 
circadian rhythm process that was specific for this timepoint. First, we validated the expression of 
specific genes involved in circadian rhythm (Takahashi, 2017) observing similar trends of expression 
to those of the RNA-seq (Fig. 4F, G). Similarly to the reduced proliferation at day 2, the changes in 
circadian rhythm were viral-specific rather than cargo-specific; the change was observed at a specific 
time point regardless of the cargo (Fig. 4G). Furthermore, some of the genes involved in these 
networks (Wee1, Tef) have been described to regulate cell cycle (Russell and Nurse, 1987; Rowley, 
Hudson and Young, 1992; Yang et al., 2019). Overall, our transcriptomic data reveals changes in 
genes involved in the circadian rhythm as well as in inflammation and immunity. 
 
Discussion 
AAV8-TBG vectors are an established means for hepatocyte-specific manipulation of gene 
expression in vivo. In this study we show that AAV8-TBG vectors have both a high degree of 
specificity and minimal off-target effects. Therefore, they serve as a reliable and efficient 
experimental tool. They have a number of specific advantages over alternatives including less 
specific Cre expression systems, global gene knockout and even CRISPR-Cas9 which itself is widely 
accepted in its current form to introduce off-target Cas9 cleavage events across species and to 
activate the TP53 pathway signalling (Tsai et al., 2015; Enache et al., 2020; Garrood et al., 2021). To 
our knowledge, our study is the first one to systematically examine these effects in the liver of WT 
mice. We demonstrate that mouse health is generally unaffected by AAV8-TBG vectors as the body 
and liver weights exhibited the expected growth. No inflammatory response, either systemic or 
intrahepatic, was observed and liver histology and function remained normal. However, we have 
identified some subtle phenotypes that are induced by AAV8-TBG vectors, which should be taken 
into account when using this system for in vivo experiments in mice. These observations highlight 
that AAV8-TBG vectors are not entirely benign. 
 
The specific targeting of hepatocytes was demonstrated by 2 reporters, RFP and GFP. 
Importantly, even though there were a few labelled cells in extra-hepatic tissues in our study, AAV8-
TBG vectors showed highly specific tropism for hepatocytes as previously reported (Wang et al., 
2010; Bell, Wang, et al., 2011). When considering phenotypic modification of hepatocytes, a low 
level of off-target (i.e. non-hepatocyte) recombination is unlikely to significantly affect short term 
studies, however it should be considered particularly when performing longer term experiments 





















We note differences in the labelling pattern between the 2 reporters; RFP labelling was evenly 
distributed across the hepatocytes, while fluorescent intensity of GFP was more heterogeneous 
across zones, showing preference for the pericentral hepatocytes (Zone 3), but also among cells 
within the same zone. We suggest that this is explained by the different mechanisms of labelling. 
Expression of the tdTomato gene is endogenously regulated and protein expression depends on 
recombination following Cre expression by the AAV8-TBG vector; once Cre is expressed and the LSL 
cassette excised, there is continuous RFP expression from the Rosa26 locus. On the other hand, GFP 
is expressed directly from the AAV8-TBG vector; therefore, its expression is predicted to vary from 
cell to cell depending on the quantity of viral copies delivered to each cell. The preferential labelling 
of pericentral hepatocytes by AAV8-TBG-GFP in mice has been demonstrated by others (Wang et al., 
2010; Bell, Wang, et al., 2011) but the exact mechanism remains unclear. It has been reported that a 
stronger “pericentral tropism” of AAV8 may underlie this (Bell, Wang, et al., 2011), rather than 
differential expression of TBG across the liver zones. This effect was also apparent by the zonal 
distribution of γH2AX positivity. Here we also observed zonal differences which are further 
exacerbated by the expression of Cre recombinase, further supporting a zonal preponderance for 
higher tropism/expression of cargo in pericentral hepatocytes. 
 
One of the key findings of this study is the widespread DDR observed in the liver, and to a 
lesser extend in the splenic red pulp, as manifested by the increase in γH2AX. It has been previously 
shown that AAVs can, upon infection, induce DNA damage and mobilize the DNA repair machinery of 
the host cell in order to achieve the circular episomal form in which AAVs persist in the host cell 
(Schwartz et al., 2009; Cataldi and McCarty, 2013). These studies, mostly performed in vitro, identify 
DNA-PKcs as a key mediator of this process, with γH2AX being one of the DDR components involved. 
Our study confirms the increase of hepatocellular γH2AX in mice in vivo in response to AAV-Null 
infection. In addition, the increase in γH2AX staining in the spleen (a reported target-organ of AAV8 
in other species such as the Rhesus macaque and the dog (Bell, Gao, et al., 2011; Greig et al., 2017)), 
but not in the kidney, in both the AAV-Null and the AAV-Cre groups supports a vector-, rather than 
cargo-induced DDR. The enhanced DDR observed in the liver, but not in the spleen, of the mice 
injected with AAV-Cre could be explained by additional, non-specific DNA damage induced by the Cre 
recombinase. This enzyme can unselectively cut DNA at non-Lox sites (Loonstra et al., 2001; 
Janbandhu, Moik and Fässler, 2014; Pépin et al., 2016; Lam et al., 2019). It is worth noting that, as in 
the case of GFP staining in the liver following AAV8-TBG-GFP administration, γΗ2ΑΧ showed a similar 
zonated staining pattern with stronger intensity in the pericentral area. This phenotype could be 




















Lastly, it is important to highlight that, in our study, despite the increase in hepatocellular γH2AX, 
there were no apparent changes in histology or gene expression related to DNA damage and that 
hepatocellular γH2AX expression is transient, reducing after 2 weeks. 
 
The observed decrease of proliferation on day 2 in both AAV-Null and AAV-Cre indicates that 
this is an AAV8-TBG mediated effect rather than solely one mediated by the Cre recombinase as has 
been described by others (Loonstra et al., 2001). This reduction of proliferation is unlikely to be 
biologically significant in the longer term as it affects a small proportion of liver cells (a drop of 
approximately 0.2% of cells compared to uninjected controls). Nonetheless, it is possible that the 
affected liver cells are important for specific functions, so further characterisation of this phenotype 
should be considered depending on the experimental question being tested. One transcriptional 
process that was altered in AAV8-TBG-treated mice was the circadian rhythm, with the changes 
taking place on day 2. Circadian rhythm is classically viewed as an internal biological clock manifested 
by oscillations in gene expression and which is mainly affected by photoperiodism. The liver however 
has an additional autonomous internal clock and thus it is not entirely dependent on photoperiodism 
(Koronowski et al., 2019; Li et al., 2020). Our transcriptomics analysis identified several genes 
involved in circadian rhythm that are differentially expressed at day 2. As some of these genes have 
been implicated in the control of cell cycle (Matsuo et al., 2003; Zhou et al., 2018), It is possible that 
these transcriptional changes are related to the mild decrease in hepatic proliferation we observed 
at day 2.  
 
Our transcriptomics analysis of whole liver lysates revealed that AAV8-TBG vectors can induce 
transcriptional changes in the liver. Regarding the variance observed in the PCA plots, we believe 
that the major driver of the Principal component 1 (PC1) is inter-mouse biological variability driven 
by differences between inbred mouse litters. No specific pathways were responsible for this variance 
and in particular, after reanalysis the 5 outlying samples on this axis are probably littermates from a 
separate litter which was relatively biologically “distant” from the other litters of the study. On the 
other hand, PC2 (16.9% of variation) was mostly driven by the effect of the AAV vector, and 
particularly separated the uninjected control mice from those that received the AAV-Null vector. This 
is further supported by the observation that the rest of the mice cluster together on the PCA, 






















The most prominent transcriptional changes identified in GO analysis are related to infection 
and inflammation processes and were observed in all the time points of the study. Given the viral 
nature of AAV8-TBG vectors, it is perhaps unsurprising to observe these transcriptional responses in 
the transduced cells. However, in our hands, this transcriptional response to infection did not result 
in a demonstrable immune response, as manifested by the stable proportion of hepatic immune cells 
at all time points. This is also supported by a similar study in Rhesus macaques where it was shown 
that AAV8-TBG administration induces minimal immune response in the liver (Greig et al., 2017). 
Nevertheless, these transcriptional changes should be considered in experiments with AAV8-TBG, 
especially when the focus of the study is related to the immune system and/or inflammation.  
 
One limitation of our work is that we have not explored the longer term consequences of 
AAV8 use in WT animals. We have observed long term hepatic expression of GFP in mice at 100 days 
following AAV8-TBG-GFP administration (Barthet et al., 2021). Persistent expression of AAV8-TBG-
driven GFP in the liver suggests persistence of AAV8-TBG vectors in the hepatocytes. Therefore, it 
would be interesting to characterise the long term effects of AAV8-TBG vectors in mice. 
 
In this study we describe the short term off-target effects (i.e. effects on hepatocytes, and by 
extension on the whole organism, that occur by AAV8-TBG transduction without genetic 
recombination) of systemic administration of AAV8-TBG vectors in mice at a dose relevant for target 
delivery across the entire hepatocyte population. Although other studies have reported some 
aspects of off-target effects of AAVs, these have mostly been performed in vitro and only explored 
specific hypothesis driven effects. In our study, the use of WT C57BL/6J mice to map the AAV8-TBG 
off-target effects, both systemic and liver-specific, makes our data relevant to that of other 
researchers. Additionally, the unbiased transcriptomics analysis serves to generally reassure about a 
lack of major off-target effects within hepatocytes when using this vector system, whilst highlighting 
specific phenotypes that would need to be controlled for in an experiment with AAV8-TBG vectors. 
In conclusion, our data show that AAV8-TBG vectors are a reliable and efficient tool for hepatocyte-
specific genetic manipulation with minimal off-target effects. 
 
Materials and Methods 
Animal experiments 
9-10 weeks old male C57BL/6J WT mice (Mus musculus) were purchased from Charles River 
UK. To minimise biological variability we obtained mice from as few litters as possible. The mice were 




















standard conditions with a 12 hr day/night cycle and ad libitum access to food and water. All 
experiments were carried out with ethical permission from the Animal Welfare and Ethical Review 
Body (AWERB) and in accordance with the ARRIVE guidelines (du Sert et al., 2020) and the Home 
Office guidelines (UK licence 70/8891; protocol 2). 
 
AAV8 experimentation was performed as previously described (Bird et al., 2018). Briefly, stock 
AAV8.TBG.PI.Cre.rBG (AAV8-TBG-Cre) (Addgene, 107787-AAV8) or AAV8.TBG.PI.Null.bGH (AAV8-
TBG-Null) (Addgene, 105536-AAV8) (stored at -80 oC) was thawed on ice, diluted in sterile PBS to 
achieve a working titre of 2x1012 genetic copies (GC)/ml and was subsequently stored at -20 oC until 
usage. On the day of the injection the diluted AAV was thawed and each mouse was injected via the 
tail vein with 100μl (2x1011 GC/mouse; mice in this study weighed from 22.4 – 29.4g at the time of 
injection). This dose has been previously shown to result in genetic recombination of nearly the total 
hepatocyte population (Bird et al., 2018). All mice were weighed on injection day (day 0) and on their 
respective cull day. Changes in body weight were compared to published data for this mouse strain 
(The Jackson Laboratory, Body Weight Chart #000664, URL (accessed on 26/11/2020): 
https://www.jax.org/jax-mice-and-services/strain-data-sheet-pages/body-weight-chart-000664#. 
The mice were sacrificed 2, 4, 7 or 14 days post AAV8-TBG administration. Male C57BL/6J mice from 
the same batch and of the same age which were not injected with AAV8-TBG (uninjected controls) 
served as baseline controls. All mice were culled between the hours of 11:00 and 15:00 on the day of 
harvest. All mice were injected with BrdU (Amersham, RPN201, 250μl per mouse) intraperitoneally 2 
hrs before culling.  
 
For the confirmation of tissue specificity of AAV8-TBG we used 8-12 weeks old male mice on a 
C57BL/6 background that were homogygotes for the R26RLSL-tdTomato allele (LSL-RFP) (Madisen et 
al., 2010). These mice were injected on the same day with both AAV8-TBG-Cre and 
AAV8.TBG.PI.eGFP.WPRE.bGH (AAV8-TBG-GFP) (Addgene, 105535-AAV8), both at a dose of 2 x 1011 
GC/mouse as described above. These mice were culled 7 days post AAV8-TBG administration. LSL-
RFP mice that were injected with 2 x 1011 GC of AAV8-TBG-Null and culled 7 days post injection 
served as controls for RFP expression. 
 
Mice were euthanized by CO2 inhalation and their blood was collected immediately by cardiac 
puncture into EDTA-coated tubes (Sarstedt) for haematology or into lithium heparin-coated tubes 
(Sarstedt) for plasma biochemistry (plasma separation was performed by centrifugation at 2350g for 




















were recorded post mortem. The caudate lobe of the liver was immediately frozen in liquid nitrogen, 
the left median lobe was frozen on dry ice and the rest of the liver was fixed for 24 hours in 10% 
neutral buffered formalin (in PBS), then changed to 70% ethanol before embedding. 
 
As these are observational studies, power calculations were not routinely performed; 
however, animal numbers were chosen to reflect the expected magnitude of response taking into 
account the variability observed in pilot experiments and previous experience in transcriptomic 
analyses. For all experiments the number of biological replicates ≥ 3 mice per cohort. 
 
Haematology and plasma biochemistry analysis 
Whole blood haematology was performed using an IDEXX ProCyte Dx analyzer on whole blood 
collected in EDTA-coated tubes (Sarstedt). Biochemical analysis of plasma was carried out using a 
Siemens Dimension Xpand Clinical Chemistry Analyzer following International Federation of Clinical 
Chemistry (IFCC) approved methods. 
 
Histology 
4μm tissue sections underwent antigen retrieval and then were sequentially incubated with 
the primary and secondary antibody. Detection was performed with 3,3'-Diaminobenzidine (DAB) 
and the sections were counterstained with Haematoxylin Z. Details about the antibodies and 
reagents can be found in Fig. S6. 
 
 Images were obtained on a Zeiss Axiovert 200 microscope using a Zeiss Axiocam MRc camera. 
For image analysis, stained slides were scanned using a Leica Aperio AT2 slide scanner (Leica 
Microsystems, UK) at 20x magnification. Quantification of blinded stained histologic sections was 
performed using the HALO image analysis software (V3.1.1076.363, Indica Labs). All of the slides 
except for the slides from day 14 were stained for a specific antibody in the same batch and 
processed at the same time in an autostainer, strictly keeping all incubation times (including that of 
DAB development) the same for all the samples. The slides from the day 14 timepoint were stained 
as a separate batch. 
 
For multiplex immunofluorescence, 4μm liver sections were retrieved for 25 minutes in Citrate 
buffer (pH 6) and were incubated with antibodies against GFP (Abcam, ab13970, 1:500), RFP 
(Rockland, 600-401-379, 1:200) and HNF4a (Santa Cruz, sc6556, 1:40) overnight at 4 oC. This was 




















for 1 hour at room temperature. Images were obtained using a Zeiss 710 upright confocal Z6008 
microscope. For the quantification, slides were scanned with the Opera Phenix scanner (Perkin 
Elmer) at 20x magnification. For the analysis of scanned sections, the Harmony Columbus software 
(Perkin Elmer) was used to create an algorithm which was subsequently used to quantify 20 random 
fields of view. 
 
RNA extraction 
RNA extraction was performed using the Qiagen RNeasy kit (74104, Qiagen UK) as per the 
manufacturer’s instructions, including the optional DNase I step. Snap frozen caudate lobe (20-30mg) 
was homogenized using the Precellys Evolution homogenizer (Cat. Number P000062-PEVO0-A, 
“MET” programme) in 600µl buffer RLT/1% β-mercaptoethanol in Precellys lysing kit tubes CK14 
(Precellys, P000912-LYSKO-A.0). The RNA was eluted in 30μl RNase-free water. RNA integrity and 
concentration were confirmed by agarose gel electrophoresis and by using the Nanodrop 2000 
(Thermo Fisher Scientific) respectively. All samples had a 260/280 ratio ≥ 2. 
 
Quantitative reverse transcription PCR (RT-qPCR) 
For RT-qPCR, RNA was extracted as described above. cDNA was generated from 1μg of RNA 
using the Qiagen QuantiTect Reverse transcription Kit (205313, Qiagen UK) on a PTC-200 thermal 
cycler (MJ Research) according to the manufacturer’s instructions. Omission of Reverse Transcriptase 
and a template-free reaction were used as negative controls. Quantitative real time PCR was 
performed with the SYBR Green system (204145, Qiagen UK) and using primers from Qiagen 
targeting Per1 (QT00113337), Per3 (QT00133455) or Wee1 (QT00157696) using a QuantStudio 5 Real 
time PCR system (Thermo Fisher Scientific, A28140) in a 384 well plate setting (final reaction volume 
10μl per well). Each biological replicate (mouse) was run in triplicate and 18S ribosomal RNA (Rn18S, 
Qiagen, QT02448075) was used as a house keeping gene for normalization. 
 
RNA-seq analysis 
Purified RNA was tested on an Agilent 2200 TapeStation (D1000 screentape) using RNA 
screentape and samples with a RIN value greater than 7 were further processed for library 
preparation. RNA at a concentration of 20ng/µl (1µg RNA in 50µl RNase-free water) was used to 
prepare libraries using the TruSeq Stranded mRNA Kit. Agilent 2200 Tapestation was used to check 
the quality of the libraries and Qubit (Thermo Fisher Scientific) was used to assess library quantity. 
The libraries were then run on the Illumina NextSeq 500 using the High Output 75 cycles kit (single 




















Raw BCL files were converted to FASTQ files using bcl2fastq2-v2.19.1 and were aligned to the 
mouse genome (GRCm38) using Hisat2 (v 2.1.0) and raw counts were generated using featureCounts 
and the GRCm38 Gencode annotation v 84. Differential gene expression was performed using edgeR. 
All RNA-seq analysis graphs were generated using standard R packages. Gene ontology was 
performed using g:Profiler (Raudvere et al., 2019). The raw data can be found on the Gene 
Expression Omnibus (GEO) repository: GSE165651. 
 
Statistical analyses 
Statistical analyses were performed using the Prism 9 Software (GraphPad Software, Inc.). The 
Shapiro-Wilk test was used to assess whether data were normally distributed. For normally 
distributed data, either One-way ANOVA, 2-way ANOVA or the Brown-Forsythe and Welch ANOVA 
test was used to compare the differences between each time point and the uninjected controls. 
Unpaired t-test was used for comparisons within time points (i.e. between AAV-Null and AAV-Cre at 
a specific time point). The Kruskal-Wallis test was performed for non parametric data, comparing the 
differences between the uninjected mice and each timepoint. All figures were created using the 
Scribus Software (v1.4.7, G.N.U. general public licence). All data points on line graphs represent 
mean ± Standard Error of Mean (S.E.M.). In bar graphs, bars represent mean ± Standard Error of 
Mean and each dot represents a single mouse. In all graphs ≥4 biological replicates (mice) are used 
for each time point. P values are: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P <0 .001 and ∗∗∗∗P <0 .0001. 
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Figure 1: AAV8-TBG vectors specifically target the hepatocytes. 
(A) Schematic of the experimental design; 8-12 week old male LSL-RFP mice on a C57BL/6 
background (n=6) were i.v. injected with AAV-Cre and AAV-GFP at the same dose (2x1011 GC/mouse). 
LSL-RFP mice (n=4) injected with AAV-Null served as controls. 7 days post injection their livers were 
harvested for analysis. (B) Representative images from liver sections stained for DAPI (blue), GFP 
(green), RFP (yellow) and the hepatocyte-specific marker HNF4α (magenta), showing the 
hepatocellular specificity of the AAV8-TBG vectors. Arrows highlight the unlabelled bile ducts. CV = 
Central Vein; PV = Portal Vein. (C) Quantification of GFP+ and RFP+ hepatocytes (i.e. HNF4a+ cells) in 
the livers of the 6 mice described in Fig. 1A and 1B, shown as percentage of total hepatocytes. (D) 
Quantification of RFP+ and GFP+ bile duct cells in the livers of the 6 mice described in Fig. 1A and 1B. 
(E) Representative images of GFP immunohistochemistry in the pancreas, duodenum, kidney, heart, 
lung and spleen of mice injected with AAV-Cre and AAV-GFP. The inset images are from GFP-stained 
liver sections from uninjected WT mice (i.e. mice not injected with either AAV-Cre or AAV-GFP, 
representative images from n=3 mice). Arrows highlight GFP+ cells (F) Immunohistochemistry for RFP 
in the kidney, pancreas, spleen, heart, lung and duodenum of the mice described in Fig. 1A. Arrows 
























Figure 2: Systemic administration of AAV8-TBG has minimal effects on general health 
causing neither liver injury nor impaired liver function. 
(A) Schematic of experimental outline. Male C57BL/6J WT mice (n=56) were injected i.v. with 
either AAV-Null or AAV-Cre. Uninjected control mice (n=6) from the same stock were culled on the 
day that the rest of the mice were injected with AAV8-TBG (day 0). The injected mice were culled 2 
(n=12; 6 AAV-Null and 6 AAV-Cre), 4 (n=16; 8 AAV-Null and 8 AAV-Cre), 7 (n=18; 9 AAV-Null and 9 
AAV-Cre) or 14 (n=10; 5 AAV-Null and 5 AAV-Cre) days after injection. (B) Body weight at cull in 
relation to body weight at day 0 for the mice described in Fig. 2A. Kruskal-Wallis test showed no 
statistically significant differences. (C) Haematocrit and Platelet counts for the mice described in Fig. 
2A. One-way ANOVA showed no statistically significant differences. (D) Circulating White Blood Cell 
counts for the mice described in Fig. 2A. Kruskal-Wallis test showed no statistically significant 
differences. (E) Absolute blood counts of circulating Neutrophils, Monocytes and Lymphocytes for 
the mice described in Fig. 2A. Kruskal-Wallis test (for Neutrophils and Monocytes) or One-way 
ANOVA (for Lymphocytes) showed no statistically significant differences. Data are mean ± S.E.M. (F) 
Liver weight to body weight ratio (LW:BW) for the mice described in Fig. 2A. Kruskal-Wallis test 
showed no statistically significant differences. (G) Alanine aminotransferase (ALT), Alkaline 
phosphatase (ALP) and Total Bilirubin (TB) in the plasma of the mice described in Fig. 2A. Kruskal-























Figure 3: AAV8-TBG vectors affect the hepatocellular cell cycle and result in DNA 
damage response. 
(A) Quantification of hepatic CD45, Ly6G, F4/80 and CD3 based on positive area/total liver 
area (CD45, F4/80) or positive cells as a percentage of total cells (CD3, Ly6G) after 
immunohistochemical detection (representative images for each time point shown in Fig. S2, S3). 
Kruskal-Wallis test (for CD3 and Ly6G) or Brown-Forsythe and Welch ANOVA (for CD45 and F4/80) 
showed no statistically significant differences. (B) Quantification of liver P21+ cells presented after 
immunohistochemical detection (representative images for each time point in Fig. S3). Data are 
presented as percentage of total liver cells. Brown-Forsythe and Welch ANOVA showed no 
statistically significant differences. (C) Quantification of liver cells positive for the S-phase marker 
BrdU and representative immunohistochemistry images (additional images for each time point are 
shown in Fig. S3); (D) Quantification of γH2AX+ liver cells and representative immunohistochemistry 
images (additional images for each time point are shown in Fig. S4). Brown-Forsythe and Welch 




















14 time point (AAV-Null VS AAV-Cre). P= **<0.01. (E) Representative liver section stained for γH2AX 
showing zonal staining particularly in the pericentral area (Zone 3). CV = Central vein, PV = Portal 
vein. (F) Quantification of γH2AX+ spleen cells (representative images for each time point in Fig. S4). 
Brown-Forsythe and Welch ANOVA showed no statistically significant differences. (G) Quantification 
of γH2AX+ kidney cells (representative images for each time point in Fig. S4). Brown-Forsythe and 
Welch ANOVA showed no statistically significant differences. For all graphs n=4 in all groups apart 
from day 7 and day 14 time points where n=5 for each group. For each graph data are mean ± S.E.M 












































Figure 4: Short-term temporal effects of AAV8-TBG upon the liver transcriptome. 
(A) Schematic of the samples used for RNA-seq. Whole liver lysates from 4 uninjected, 13 AAV-
Null (n=4 at day 2, n=4 at day 4 and n=5 at day 7 post injection) and 11 AAV-Cre (n=4 at day 2, n=4 at 
day 4 and n=3 at day 7 post injection) mice were used. (B) Principal Component Analysis (PCA) plot 
of the samples used for RNA-seq. (C) Quantity of the transcripts encoded by AAV-Cre (sequence of 
the Cre recombinase) or AAV-Null (scrambled sequence) in the different conditions represented as 
Fragments Per Kilobase of transcript per Million mapped reads (FPKMs). 2-way ANOVA. ∗P < 0.05; 
∗∗∗∗P <0 .0001. (D) Table showing the number of differentially expressed genes (DEGs) for each 
group compared to uninjected. FDR<0.05. (E) Gene Ontology (GO) analysis comparing the 
differentially expressed genes shared between AAV-Null and AAV-Cre mice after each group is 
compared to uninjected mice (AAV-Null VS uninjected ∩ AAV-Cre VS uninjected) mice at day 2, 4 and 
7. (F) RT-qPCR for Per1, Per3 and Wee1. Fold change expression was calculated by normalizing to the 
uninjected mice for each gene. n=4 for each group. Kruskal-Wallis test (Per1) or one-way ANOVA 
(Per3, Wee1). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P <0 .001 and ∗∗∗∗P <0 .0001. The bars are mean ± S.E.M. 
(G) Unsupervised heatmap showing the differential expression of major genes involved in circadian 
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Fig. S1. Multiplex IF controls and clinical p arameters of the mice after AAV8-TBG 
injection. 
(A) Technical control (omission of the anti-RFP primary antibody) of the multiplex
immunofluorescent stain shown in Fig.1B. Blue=DAPI, green=GFP, yellow=RFP,
magenta=HNF4α (B) Chromogen-based immunohistochemistry for RFP on liver sections
of LSL-tdTomato mice 7 days post AAV-Null or AAV-Cre. Image inset shows RFP- bile
duct cells. (C) Body weight on the day of study initiation of the mice described in Fig. 2A.
Bars are mean ± S.E.M and each dot represents one mouse. One-way ANOVA showed no
statistically significant differences. (D) Relative counts of circulating neutrophils, monocytes
and lymphocytes as a percentage of circulating total white blood cells of the mice described
in Fig. 2A. Kruskal-Wallis test showed no statistically significant differences. (E) Liver
weight of the uninjected, AAV-Null and AAV-Cre mice at the time of harvest. One-way
ANOVA showed no statistically significant differences. Dots are mean ± S.E.M. (F) Plasma
levels of Total Protein, Albumin, Globulin  and Albumin:Globulin ratio. One-way ANOVA
(Total protein) or Kruskal-Wallis test (Globulin) showed no statistically significant
differences. The Kruskal-Wallis test was used for Albumin and the Brown-Forsythe and
Welch ANOVA for the Albumin:Globulin ratio. P= * < 0.05, **** < 0.0001. Dots are mean ±
S.E.M. (G) Quantification of Cleaved Caspase 3 (CC3) positive liver area of the mice
described in 2A (n=4 for each group except day 7 and day 14 where n=5 for both AAV-Null
and AAV-Cre groups). Kruskal-Wallis test showed no statistically significant differences.
Dots are mean ± S.E.M. (H) Plasma levels of Urea and Creatinine. One-way ANOVA
showed no statistically significant differences for Urea. The Brown-Forsythe test was used
for Creatinine; P= * < 0.05. (I) Quantification of γH2AX strongly positive liver cells of the
mice described in 2A (n=4 for each group except day 7 and day 14 where n=5 for both
AAV-Null and AAV-Cre groups). Representative images for each time point are shown in
Fig. S4. Brown-Forsythe and Welch ANOVA, P= *< 0.05, **<0.01. Dots are mean ± S.E.M.
All scale bars are 50μm.



























































Fig.  S2. Effects of AAV8-TBG on liver cell death and inflammation. 
Representative images of H&E and immunohistochemistry for cleaved caspase-3 (CC3), CD45 and Ly6G. 
n=4 for each group except day 7 and day 14 where n=5. Scale bars are 50μm. 




























































Fig.  S3. Effects of AAV8-TBG on hepatic inflammation. 
Representative photos of immunohistochemistry for F4/80, CD3, p21 and BrdU. n=4 for each group 
except day 7 and day 14 where n=5. Scale bars are 50μm. 




























































Fig. S4. Effects of AAV8-TBG on cell cycle and DNA damage response. 
Representative photos of immunohistochemistry for γH2AX on liver, spleen and kidney sections. n=4 
for each group except day 7 and day 14 where n=5. Scale bars are 50μm.
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Fig. S5. Differentially expressed genes from the RNA-seq analysis. 
Tables with the top 10 differentially expressed genes (DEGs) compared to the uninjected mice for 
each group. 
























Fig. S6. Details of the antibodies and reagents use to perform 
immunohistochemistry. 
(A) Table showing the methodology that was used to perform the immunohistochemistry stainings.
(B) Table showing which reagents were used for immunohistochemistry.
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